A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 diabetes

Registry ID

EUCTR2006-001218-34

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2006-09-20

Completion date

2007-11-20

Last update

2026-08-16

Conditions

• Type II Diabetes

Summary

To demonstrate the effect of 4 week treatment with vildagliptin compared to placebo on the glucagon counterregulatory response to hypoglycemia in patients with T2DM, assessed as mean glucagon level (AUC / sampling period) of the last 30 min of the 2.5 mM hypoglycemic clamp step

Locations

• , , Sweden

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
• Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
• Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
• Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

View on source registry